Phathom Pharmaceuticals Inc (PHAT) Stock AnalysisPHATPhathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phathom Pharmaceuticals (PHAT) is not a good buy right now due to its current price of $5.74, which is significantly below the average analyst price target of $20-$22. The stock has experienced a 63.46% year-to-date decline and a 17.05% drop over the last five days, indicating a bearish trend. Additionally, the RSI is at a low 19.803, suggesting oversold conditions, but the overall financial performance remains concerning with a gross margin of 79.68% in Q2 2026, while the company still faces challenges with a net income loss of $17.58 million in the same quarter. The primary risk is the ongoing legal challenge against the FDA, which could further impact market confidence.